GAITHERSBURG, Md., Oct. 13, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has finalized ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min After weeks of uncertainty and ...
The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions. By Christina Jewett and Apoorva Mandavilli The Food and Drug Administration on ...
Approval had been delayed since April 1 Company said received OK after substantial back and forth Will need additional approval to change strain of vaccine May 17 (Reuters) - The U.S. Food and Drug ...
Novavax (NVAX) issued the following statement on publicly available COVID-19 vaccine data: “Novavax is a U.S.-based biotechnology company that is proud to have successfully developed a COVID-19 ...
Novavax aims to convert emergency authorization to full approval FDA's request boosts Novavax shares by 18% Analysts confident in Novavax's approval despite past hurdles April 23 (Reuters) - Novavax ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results